2025
Hypertension after solid-organ transplantation: special considerations for management
Feliberti J, Alam A, Maulion C. Hypertension after solid-organ transplantation: special considerations for management. Current Opinion In Cardiology 2025, 40: 193-198. PMID: 40401425, DOI: 10.1097/hco.0000000000001230.Peer-Reviewed Original ResearchConceptsBaroreflex activation therapySolid organ transplantationHeart transplantationRenal denervationGLP-1R agonistsGLP-1RActive therapyMedical managementMedical management of hypertensionTherapy of heart failureReinitiation of therapyAngiotensin-converting enzyme inhibitorsCalcium channel blockersAngiotensin receptor blockersCardiovascular outcome trialsGlucagon-like peptide-1 receptorOptimal medical managementIncidence of hypertensionManagement of hypertensionImmunosuppressive therapyRefractory hypertensionPeptide-1 receptorChannel blockersRenal transplantationReceptor blockersMoving Beyond Desensitization to Tolerance in Food Allergy
Flom J, Shreffler W, Perrett K. Moving Beyond Desensitization to Tolerance in Food Allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 741-744. PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protection
2024
Cancer Survivorship at Stanford Cancer Institute
Smith S, Steele N, Kim J, Yurkiewicz I, Benedict C, Trivedi R, Heathcote L, Simon P, Bugos K, Clayton A, Palesh O, Schapira L. Cancer Survivorship at Stanford Cancer Institute. Journal Of Cancer Survivorship 2024, 18: 53-58. PMID: 38183579, PMCID: PMC11697835, DOI: 10.1007/s11764-023-01523-w.Peer-Reviewed Original ResearchCancer survivorship programStanford Cancer InstituteSurvivorship clinicSurvivorship programsCancer InstituteCare deliveryOutcomes of patientsPrimary care cliniciansClinical care modelsClinical care deliveryQuality of lifePatient-oriented researchActive therapyCare cliniciansCancer survivorsOutpatient clinicCancer carePrimary careDisease groupCancer survivorshipCare modelSurvivorship researchClinical careHigh riskSpecialty services
2022
Oncologic emergencies and urgencies: A comprehensive review
Rothberg BE, Quest T, Yeung S, Pelosof L, Gerber D, Seltzer J, Bischof J, Thomas C, Akhter N, Mamtani M, Stutman R, Baugh C, Anantharaman V, Pettit N, Klotz A, Gibbs M, Kyriacou D. Oncologic emergencies and urgencies: A comprehensive review. CA A Cancer Journal For Clinicians 2022, 72: 570-593. PMID: 35653456, DOI: 10.3322/caac.21727.Peer-Reviewed Original ResearchConceptsEmergency departmentChimeric antigen receptor T cellsMalignant spinal cord compressionImmune checkpoint inhibitorsTumor lysis syndromeAntidiuretic hormone secretionSpinal cord compressionChemotherapy-induced mucositisMechanical bowel obstructionCheckpoint inhibitorsFebrile neutropeniaMalignant effusionsSystemic treatmentUrgent care centersAcute decompensationCord compressionT cellsOncologic emergencyVenous thromboembolismBowel obstructionPainful crisesPoint-of-care referencesActive therapyHormone secretionOutpatient oncologists
2021
Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients
Gorfinkel L, Hansen CE, Teng W, Shabanova V, Prozora S, Rodwin R, Qadri U, Manghi T, Emerson B, Riera A. Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients. Pediatric Blood & Cancer 2021, 69: e29519. PMID: 34939321, DOI: 10.1002/pbc.29519.Peer-Reviewed Original ResearchConceptsPediatric emergency departmentPeripheral blood culturesPediatric oncology patientsFebrile oncology patientsClinical decision ruleOncology patientsBlood culturesBloodstream infectionsPositive peripheral blood cultureDiagnostic prediction toolsInternal validationRetrospective chart reviewAcute myeloid leukemia diagnosisRecent systematic reviewClinical prediction modelReceiver operator curveVasopressor supportActive therapyChart reviewDerivation cohortIndependent predictorsEmergency departmentPatientsSystematic reviewOperator curveDevelopment and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience
Rabiee A, Taddei T, Aytaman A, Rogal SS, Kaplan DE, Morgan TR. Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. Cancers 2021, 13: 4849. PMID: 34638333, PMCID: PMC8508370, DOI: 10.3390/cancers13194849.Peer-Reviewed Original ResearchVeterans Affairs Health Care SystemMultidisciplinary liver tumor boardHealth care systemTumor boardCare systemIntegrated health care systemSingle care providerMultidisciplinary tumor boardUnnecessary invasive proceduresVirtual tumor boardsHealth care costsActive therapyVA centersPatient outcomesHepatology careHigher oddsCare providersInvasive proceduresCare costsSignificant heterogeneityCareHealthcare deliveryMortalitySignificant barriersVAImpact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization
Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.Peer-Reviewed Original ResearchConceptsUrgent care centersCare centerHospitalization ratesLarge tertiary academic centerAcute care useAcute care utilizationEmergency department presentationsTertiary academic centerEmergency room utilizationCancer care costsPeriod 1 yearProvider visitsActive therapyHospital admissionPrimary outcomeCare utilizationOncology patientsAcute careCare useClinic capacityPatient awarenessPhysician comfortClinical pathwayPatientsAcademic centers
2020
Adherence to study drug in a stroke prevention trial"?>
Kiran A, Viscoli CM, Furie KL, Gorman M, Kernan WN. Adherence to study drug in a stroke prevention trial"?>. Journal Of Stroke And Cerebrovascular Diseases 2020, 29: 105048. PMID: 32912514, PMCID: PMC7487071, DOI: 10.1016/j.jstrokecerebrovasdis.2020.105048.Peer-Reviewed Original ResearchConceptsRate of discontinuationStudy drugDrug holidayTreatment groupsActive study drugAdverse effectsInsulin Resistance InterventionPremature drug discontinuationRecent ischemic strokeStroke Prevention TrialDouble-blind trialTransient ischemic attackClinical trial researchPhases of adherenceDrug discontinuationIschemic attackStroke preventionDiscontinuation ratesIschemic strokeActive therapyMedical therapyPatient adherencePrevention trialsStroke trialsPharmacodynamic effectsComparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses.
Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, Ahmadzai N, Skidmore B, Morgan SC, Bordeleau L, Ginex PK, Sadeghirad B, Morgan RL, Cole KM, Clemons M. Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. Oncology Nursing Forum 2020, 47: e86-e106. PMID: 32555553, PMCID: PMC7891229, DOI: 10.1188/20.onf.e86-e106.Peer-Reviewed Original ResearchConceptsHot flash frequencyHot flashesProstate cancerHot flash scoreHistory of breastHot flash severityQuality of lifeFlash frequencyActive therapyPatients' qualitySystematic reviewAbstractTextMeta-AnalysisNarrative synthesisMore interventionsDATA EVALUATIONLiterature searchPatientsTherapyCancerBreastLittle dataInterventionMinimal dataTreatmentManagement and treatment of nocturnal enuresis—an updated standardization document from the International Children's Continence Society
Nevéus T, Fonseca E, Franco I, Kawauchi A, Kovacevic L, Nieuwhof-Leppink A, Raes A, Tekgül S, Yang S, Rittig S. Management and treatment of nocturnal enuresis—an updated standardization document from the International Children's Continence Society. Journal Of Pediatric Urology 2020, 16: 10-19. PMID: 32278657, DOI: 10.1016/j.jpurol.2019.12.020.Peer-Reviewed Original ResearchConceptsInternational Children's Continence SocietyInternational Children's Continence Society membersConcomitant sleep-disordered breathingFirst-line treatment modalitySleep-disordered breathingUrinary tract infectionTreatment of childrenNonmonosymptomatic enuresisAntidepressant treatmentDisordered breathingMonosymptomatic enuresisSleep apneaUrodynamic assessmentDaytime incontinenceAnticholinergic treatmentFirst-lineTract infectionsTreatment modalitiesAirway obstructionBlood testsActive therapyEvidence-based literatureEnuretic childrenEnuresis alarmComorbid conditions
2019
Reconsidering Nutritional Support in Critically Ill Patients
Korwin A, Honiden S. Reconsidering Nutritional Support in Critically Ill Patients. Seminars In Respiratory And Critical Care Medicine 2019, 40: 580-593. PMID: 31826259, DOI: 10.1055/s-0039-1697967.Peer-Reviewed Original ResearchConceptsIntensive care unitIll patientsGood nutrition practicesNeeds of patientsProvision of nutritionICU nutritionSupportive careActive therapyNutritional supportCare unitFeeding interruptionsCritical careNutrition practicesGastrointestinal physiologyPatientsCircadian rhythmFeeding pumpProcess of recoveryCareMore researchNutritionProtein synthesisNon-continuous modeTherapyCliniciansEpidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advances
2017
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.Peer-Reviewed Original ResearchConceptsPlasma cell disordersSerologic responseInfluenza vaccinationInfluenza vaccineMultiple myelomaCell disordersInfluenza infectionVaccination strategiesHigh-dose influenza vaccineInactivated trivalent influenza vaccineLaboratory-confirmed influenza infectionBooster vaccination strategiesStandard vaccination strategyTwo-dose seriesLaboratory-confirmed influenzaSeasonal influenza vaccinationTrivalent influenza vaccineSingle-arm trialPlasma cell dyscrasiaDisease response assessmentLogistic regression modelsSeroprotection ratesActive therapyAdverse eventsPartial responseAssociation of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChi-Square DistributionDelivery of Health Care, IntegratedFemaleGastroenterologistsHumansKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOncologistsPatient Care TeamPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSpecializationSurgeonsTime FactorsTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsRetrospective cohort studyMultidisciplinary tumor boardHealth system factorsHepatocellular carcinomaHCC therapyCohort studyOverall survivalTumor boardTime-varying Cox proportional hazards modelsCox proportional hazards modelActive hepatocellular carcinomaOutcomes of patientsProportional hazards modelHepatocellular carcinoma treatmentVeterans Administration HospitalSystem factorsLiver transplantationActive therapyLiver resectionTransarterial therapiesMedical oncologistsMultidisciplinary careSubspecialist carePatient survivalAblative therapy
2016
Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database.
Scott B, Kiselev P, Fliss A, Huang M, Steensma D, Ma X, Swern A, Sugrue M. Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database. Journal Of Clinical Oncology 2016, 34: e18548-e18548. DOI: 10.1200/jco.2016.34.15_suppl.e18548.Peer-Reviewed Original Research
2013
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions
2012
Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007
Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA. Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007. International Journal Of Radiation Oncology • Biology • Physics 2012, 82: e781-e786. PMID: 22331001, PMCID: PMC3418871, DOI: 10.1016/j.ijrobp.2011.11.024.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyThree-dimensional conformal radiation therapyProportion of patientsInvasive radical prostatectomyOpen surgical approachProstate cancerIntensity-modulated radiation therapyRadiation therapyDeprivation therapyConformal radiation therapyRadical prostatectomySurgical approachMedicare populationRetrospective claims-based analysisIncident prostate cancerClaims-based analysisManagement of patientsLarge clinical trialsLocalized prostate cancerTreatment of patientsExternal beam radiotherapyHealth care costsActive therapyInitial treatmentOptimal therapy
2009
Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group
Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. Journal Of Clinical Oncology 2009, 27: 6020-6020. DOI: 10.1200/jco.2009.27.15_suppl.6020.Peer-Reviewed Original ResearchGrade 5 toxicityArm 2Response rateArm 1Metastatic squamous cell carcinomaEastern Cooperative Oncology GroupCycles of therapyECOG PS 0ECOG PS 1Cooperative Oncology GroupTime of progressionSquamous cell carcinomaSCCHN cell linesPrior chemoPrimary endpointStable diseaseToxic regimenActive therapyOncology GroupPS 0Cell carcinomaNF-κβTumor sensitivityTherapyInhibits growth
2008
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer
Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 145-151. PMID: 18303435, DOI: 10.1097/jto.0b013e318160c5f1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDocetaxelDrug-Related Side Effects and Adverse ReactionsFeasibility StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPatient ComplianceSurvival AnalysisTaxoidsConceptsNon-small cell lung cancerCell lung cancerAdjuvant therapySupportive therapyChemotherapy complianceLung cancerAdequate exposureResected non-small cell lung cancerAdjuvant cisplatin-based chemotherapyMulticenter phase II trialMedian age 65 yearsCycles of therapyPrimary end pointAcceptable toxicity profileBetter functional statusPhase II trialCisplatin-based chemotherapyMajority of patientsSquamous cell carcinomaAge 65 yearsAdjuvant carboplatinCommon histologyII trialIntercurrent illnessActive therapy
1999
Intracoronary radiation for patients with refractory in-stent restenosis An analysis from the wrist-crossover trial
Waksman R, Bhargava B, White R, Chan R, Gierlach L, Mehran R, Lansky A, Kent K, Mintz G, Satler L, Pichard A, Leon M. Intracoronary radiation for patients with refractory in-stent restenosis An analysis from the wrist-crossover trial. Cardiovascular Revascularization Medicine 1999, 1: 317-322. PMID: 10828560, DOI: 10.1016/s1522-1865(00)00024-x.Peer-Reviewed Original ResearchConceptsPrimary treatment groupTarget lesion revascularizationCrossover groupStent restenosisTreatment groupsClinical trialsQ-wave myocardial infarctionStent restenosis TrialAdverse cardiac eventsPrimary clinical endpointIntracoronary stent implantationRandomized clinical trialsCatheter-based interventionsCatheter-based techniquesStent neointimal formationAnginal symptomsLesion revascularizationRecurrent ISRRestenosis TrialActive therapyAngiographic outcomesCardiac eventsPlacebo armProcedural successIntracoronary radiation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply